Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

Newer

TFMG

06/23/20 10:19 PM

Post #17

Precision BioSciences, On Breakout Alert

Alert set for break above $9.10 of possible long entry .
200ma and .236 Fib resistance to breakout
Indicators bullish with room to run much higher
Company Profile
Precision BioSciences , Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS , the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC .

jondoeuk

04/23/20 9:26 PM

Post #16

The company's third trial for its anti-BCMA CAR-T therapy is now recruiting https://clinicaltrials.gov/ct2/show/NCT04171843

jondoeuk

04/07/20 9:33 PM

Post #15

A new PR https://www.globenewswire.com/news-release/2020/04/07/2012714/0/en/Precision-BioSciences-Announces-Dosing-of-First-Patient-in-Phase-1-2a-Clinical-Trial-of-PBCAR20A-for-Relapsed-Refractory-NHL-CLL-and-SLL.html

jondoeuk

04/06/20 6:47 PM

Post #14

This (COVID-19) 10K says that, as of now, the company has not experienced any delays to its ongoing or planned clinical trials, they will continue to enroll patients, and expects to provide further clinical data updates during this year from ongoing anti-CD19 trial. Also, they are continuing certain manufacturing functions, but have limited lab activities https://www.sec.gov/Archives/edgar/data/1357874/000156459020015378/dtil-8k_20200406.htm

edwardport Free

04/04/20 5:03 PM

Post #13

$4.66 and going lower

jondoeuk

03/24/20 5:07 PM

Post #12

Re: #11: @jondoeuk - The company has now filed the protocol changes

DTIL have opened a trial for its anti-CD20 CAR-T (NCT04030195) and will start with DL2. Also, they are currently producing material for the anti-BCMA CAR-T program and a trial for this will be open sometime this year (NCT04171843).

jondoeuk

03/13/20 6:39 PM

Post #11

The company has now filed the protocol changes for the anti-CD19 trial on https://clinicaltrials.gov/ct2/show/NCT03666000

jondoeuk

02/08/20 6:55 PM

Post #10

The upcoming presentation by Dr. MacLeod is entitled 'Engineering Gene-Edited Off-the-Shelf CAR T Cells to Reduce Immunogenicity and Improve Activity.'

From it: ''For our next generation of therapeutics, we are exploring gene knockout and incorporation of RNAi cassettes to modulate gene expression, with the goal of avoiding rejection, reducing T cell exhaustion, and enhancing function in the suppressive tumor microenvironment.'' https://www.pegsummit.com/TCellTherapy/